{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:19:12Z","timestamp":1791523152604,"version":"4.3.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>We treated skin sclerosis with triple therapy consisting of a glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis. The objective of this study was to analyze its effectiveness in a case series of patients who received triple therapy.<\/jats:p>\n            <jats:p>We enrolled 8 patients with diffuse cutaneous systemic sclerosis (dcSSc) who received triple therapy at our hospital from 2008 to 2016. We analyzed the mean change in the modified Rodnan skin score (mRSS), percentage of the predicted forced vital capacity (%FVC), percentage of the predicted carbon monoxide diffusing capacity (%DLCO), and serum KL-6 levels from baseline to follow-up.<\/jats:p>\n            <jats:p>All patients were treated with an intermediate dose of oral prednisolone (30.6\u200a\u00b1\u200a2.1\u200amg\/day) initially. The mean cumulative dose of intravenous cyclophosphamide was 1.4\u200a\u00b1\u200a0.2\u200ag. The mean mRSS decreased significantly at follow-up compared with that at baseline (27.0\u200a\u00b1\u200a3.3 vs 15.8\u200a\u00b1\u200a3.5; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03). At the end of the treatment, the mean %FVC and %DLCO were improved moderately, although the differences were not significant. The serum KL-6 levels decreased from 578.9\u200a\u00b1\u200a146.5 to 205.3\u200a\u00b1\u200a43.1\u200aU\/ml (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02). No significant correlation was found between the change in mRSS or disease duration and the initial skin score severity.<\/jats:p>\n            <jats:p>Triple therapy may improve skin sclerosis, with effectiveness equal or superior to other reported treatments. This preliminary case series demonstrates the potential of triple therapy for treating dcSSc. However, prospective studies with long-term follow-up should be performed to assess its role.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019301","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T07:46:54Z","timestamp":1583740014000},"page":"e19301","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis"],"prefix":"10.1097","volume":"99","author":[{"given":"Kensuke","family":"Suga","sequence":"first","affiliation":[{"name":"Division of Rheumatic Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Rheumatic Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatic Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Division of Nephrology, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hinoshita","sequence":"additional","affiliation":[{"name":"Division of Nephrology, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatic Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3]]},"reference":[{"key":"R1-20230915","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/art.22721","article-title":"Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model","volume":"56","author":"Shand","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-0172(88)90030-3","article-title":"Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients","volume":"18","author":"Lally","year":"1988","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12016-008-8114-x","article-title":"Recent Advances in the Treatment of Systemic Sclerosis","volume":"36","author":"Bournia","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1523-1747.ep12318465","article-title":"Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis","volume":"105","author":"Igarashi","year":"1995","journal-title":"J Invest Dermatol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11926-012-0304-0","article-title":"Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities","volume":"15","author":"Iwayama","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20230915","first-page":"S87","article-title":"Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement","volume":"22","author":"Takehara","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"Derk","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03009740510026896","article-title":"Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease","volume":"35","author":"Valentini","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/03009748809105267","article-title":"Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis","volume":"17","author":"Akesson","year":"1988","journal-title":"Scand J Rheumatol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0738-081X(94)90290-9","article-title":"The fibroblast in systemic sclerosis","volume":"12","author":"Sollberg","year":"1994","journal-title":"Clin Dermatol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0738-081X(94)90289-5","article-title":"Lymphocyte modulation of fibroblast function in systemic sclerosis","volume":"12","author":"Piela-Smith","year":"1994","journal-title":"Clin Dermatol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomized controlled trial (fascinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00300808","article-title":"Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study","volume":"14","author":"Sharada","year":"1994","journal-title":"Rheumatol Int"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1517\/13543784.12.3.471","article-title":"Treatment of scleroderma: an update","volume":"12","author":"Sule","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/art.11081","article-title":"Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis","volume":"48","author":"Apras","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 But Not CCL-18 Is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J Rheumatol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/s10165-011-0515-7","article-title":"Clinical features of 405 Japanese patients with systemic sclerosis","volume":"22","author":"Hashimoto","year":"2012","journal-title":"Mod Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:11:30Z","timestamp":1694819490000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019301","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}